Download PDF
Phlebologie 2017; 46(02): 98-104
DOI: 10.12687/phleb2350-2-2017
Original article
Schattauer GmbH

MRSA decolonisation using polyhexanide 0.1 % with application where necessary of systemic antibiotics

Article in several languages: English | deutsch
M. B. Lorenz
1   Klinik und Poliklinik für Hautkrankheiten, Abteilung Wundheilung und Phlebologie, Universitätsklinikum Münster, Münster, Germany
,
P. Gkogkolou
1   Klinik und Poliklinik für Hautkrankheiten, Abteilung Wundheilung und Phlebologie, Universitätsklinikum Münster, Münster, Germany
,
R. Köck
2   Institut für Medizinische Mikrobiologie, Universitätsklinikum Münster, Münster, Germany
3   Institut für Krankenhaushygiene Oldenburg, Oldenburg, Germany
,
T. Goerge
1   Klinik und Poliklinik für Hautkrankheiten, Abteilung Wundheilung und Phlebologie, Universitätsklinikum Münster, Münster, Germany
› Author Affiliations
Further Information

Publication History

Received: 02 January 2017

Accepted: 21 February 2017

Publication Date:
04 January 2018 (online)

    Permissions and Reprints

Summary

Background: Increasing infections and drug resistances lead to new treatment concepts in terms of MRSA decolonisation. An antibiotic-free decolonisation treatment with topical antiseptics is of great clinical interest. We investigated the effectiveness of MRSA decolonisation therapy using the topical antiseptic agent polyhexanide 0.1 %. If needed, a systemic antibiotic was added in case of hospitalisation, abscess formation, chronic wounds and others.

Patients and methods: 63 patients were introduced to our outpatient clinic within a period of record of 15 months. 42 (66.7 %) of them were confirmed MRSA-positive and 27 (64.3 %) of these colonised patients were included to the protocol of decolonisation. Patients who followed the protocol of decolonisation (n=27) were investigated in terms of the site of MRSA-colonisation, parameters that minimize the effect of decolonisation, spa types as well as the effectiveness of the topical antiseptic agent polyhexanide 0.1 %.

Results: 22 patients (81.5 %) were successfully decolonised within the group that followed the decolonisation protocol (n=27). Using polyhexanide 0.1 % as single treatment regime seven people (31.8 %) were successfully decolonised, whereas 15 patients (68.2 %) were in need of an additional systemic treatment with antibiotics in order to be decolonised. The implementation of one topical eradication cycle with polyhexanide 0.1 % was effective in case of an exclusive colonisation of the nose (n=3). At maximum, three decolonisation runs were necessary. Within six months of post-eradication investigations no relapses of MRSA were registered.

Conclusions: One third of the decolonised patients were successfully treated with the topical antiseptic polyhexanide 0.1 %, whereas two thirds of the patients that followed the decolonisation protocol were in need of an additional systemic antibiotic.

Keywords

Polyhexanide - MRSA - outpatients - mupirocin
 

  • References

  • 1 Atashbeyk DG. et al. Eradication of methicillin-resistant Staphylococcus aureus infection by nanoliposomes loaded with gentamicin and oleic acid. Pharm Biol 2014; 52 (Suppl. 11) 1423-1428.
    CrossrefPubMedGoogle Scholar
  • 2 ECDC.. Antimicrobial Resistance Surveillance in Europe 2010; 2011. Annual report of the EARS-Net. Stockholm: 2011
    PubMedGoogle Scholar
  • 3 Wagener J, Seybold U. (MRSA – hygiene management, diagnostics and treatment). DMW 2014; 139 (Suppl. 13) 643-654. doi:10.1055/s-0033–1359924.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Wertheim HFL. et al. Optimisation of the antibiotic policy in the Netherlands. XII. Ned Tijdschr Geneeskd 2008; 152 (Suppl. 49) 2667-2671.
    PubMedGoogle Scholar
  • 5 Reich-Schupke S. et al. Eradication of MRSA in chronic wounds of outpatients with leg ulcers is accelerated by antiseptic washes. Int J Hyg Environ Health 2010; 213 (Suppl. 02) 88-92.
    CrossrefPubMedGoogle Scholar
  • 6 KRINKO/RKI. Empfehlungen zur Prävention und Kontrolle von Methicillin-resistenten Staphylococcus aureus-Stämmen (MRSA) in medizinischen und pflegerischen Einrichtungen. Bundesgesundheitsblatt 2014; 57 (Suppl. 06) 696-732.
    Google Scholar
  • 7 RKI.. Empfehlung zur Prävention und Kontrolle von Methicillin-resistenten Staphylococcus-aureus-Stämmen (MRSA) in Krankenhäusern und anderen medizinischen Einrichtungen. Bundesgesundheitsblatt 1999; 42: 954-958.
    Google Scholar
  • 8 Harmsen D, Claus H, Witte W. et al. Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management. J Clin Microbiol 2003; 41: 5442-5448.
    CrossrefPubMedGoogle Scholar
  • 9 Mellmann A. et al. Automated DNA sequence-based early warning system for the detection of methicillin-resistant Staphylococcus aureus outbreaks. PLoS Med 2006; 3 (Suppl. 03) e33.
    CrossrefPubMedGoogle Scholar
  • 10 Mellmann A, Weniger T, Berssenbrügge C. et al. Based Upon Repeat Pattern (BURP): an algorithm to characterize the long-term evolution of Staphylococcus aureus populations based on spa polymorphisms. BMC Microbiol 2007; 7: 98.
    CrossrefPubMedGoogle Scholar
  • 11 Meyer V, Kerk N, Mellmann A. et al. MRSA eradication in dermatologic outpatients – theory and practice. J Dtsch Dermatol Ges 2012; 10: 186-196.
    PubMedGoogle Scholar
  • 12 Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI). Clin Exp Dermatol 1994; 19 (Suppl. 03) 210-216.
    CrossrefPubMedGoogle Scholar
  • 13 Cookson BD. Tonsillectomy and MRSA carriage. J Hosp Infect 2005; 61 (Suppl. 02) 176-177.
    CrossrefPubMedGoogle Scholar
  • 14 Layer F. et al. Aktuelle Daten und Trends zu Methicillin-resistenten Staphylococcus aureus (MRSA). Bundesgesundheitsblatt 2012; 55 11–12 1377-1386.
    Google Scholar
  • 15 Cuny C. et al. State-wide surveillance of antibiotic resistance patterns and spa types of methicillin-resistant Staphylococcus aureus from blood cultures in North Rhine-Westphalia, 2011–2013. Clin Microbiol Infect 2015; 21 (Suppl. 08) 750-757.
    CrossrefPubMedGoogle Scholar
  • 16 Polo Gascón MR. et al. Quality-of-life impairment in patients with livedoid vasculopathy. J Am Acad Dermatol 2014; 71 (Suppl. 05) 1024-1026.
    CrossrefPubMedGoogle Scholar
  • 17 Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004; 9 (Suppl. 02) 169-180.
    CrossrefPubMedGoogle Scholar
  • 18 Seipp HM, Stroh A. Methicillin-resistente S. aureus (MRSA) – Signifikante Reduktion von Inzidenz und Rate in einem Klinikum der Maximal-versorgung (1994–1999). Hyg Medizin 1999; 24: 224-237.
    Google Scholar
  • 19 Madeo M. Efficacy of a novel antimicrobial solution (Prontoderm) in decolonising MRSA nasal carriage. J Hosp Infect 2010; 74 (Suppl. 03) 290-291.
    CrossrefPubMedGoogle Scholar
  • 20 Jones JC. et al. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis 2007; 45 (Suppl. 05) 541-547.
    CrossrefPubMedGoogle Scholar
  • 21 Liu C, Bayer A, Cosgrove SE. et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52 (Suppl. 03) e18-55.
    CrossrefPubMedGoogle Scholar
  • 22 Ammerlaan HSM. et al. Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis 2009; 48 (Suppl. 07) 922-930.
    CrossrefPubMedGoogle Scholar
  • 23 Köck R, Becker K, Cookson B. et al. Systematic literature analysis and review of targeted preventive measures to limit healthcare-associated infections by meticillin-resistant Staphylococcus aureus. Euro Surveill. 2014 19: (29).
    PubMedGoogle Scholar
  • 24 Fabry W, Kock HJ. In-vitro activity of polyhexanide alone and in combination with antibiotics against Staphylococcus aureus. J Hosp Infect 2014; 86 (Suppl. 01) 68-72.
    CrossrefPubMedGoogle Scholar
  • 25 Ansorg R. et al. Influence of mucin on the activity of the antiseptic lavasept against Staphylococcus aureus. Chemotherapy 2002; 48 (Suppl. 03) 129-133.
    CrossrefPubMedGoogle Scholar
  • 26 Ansorg R. et al. Inhibition of the Anti-staphylococcal Activity of the Antiseptic Polihexanide by Mucin. Drug Res 2003; 53 (Suppl. 05) 368-371.
    Google Scholar
  • 27 Koburger T. et al. Standardized comparison of antiseptic efficacy of triclosan, PVP-iodine, octenidine dihydrochloride, polyhexanide and chlorhexidine digluconate. J Antimicrob Chemother 2010; 65 (Suppl. 08) 1712-1719.
    CrossrefPubMedGoogle Scholar
  • 28 Wild T, Bruckner M, Payrich M. et al. Eradication of Methicillin-Resistant Staphylococcus aureus in Pressure Ulcers Comparing a Polyhexanide-Containing Cellulose Dressing with Polyhexanide Swabs in a Prospective Randomized Study. Adv Skin Wound Care 2012; 25 (Suppl. 01) 17-22.
    CrossrefPubMedGoogle Scholar
  • 29 Landelle C, Von Dach E, Haustein T. et al. Randomized, placebo-controlled, double-blind clinical trial to evaluate the efficacy of polyhexanide for topical decolonisation of MRSA carriers. J Anti-microb Chemother 2016; 71 (Suppl. 02) 531-538.
    CrossrefPubMedGoogle Scholar
  • 30 Daeschlein G. et al. Risk factors for MRSA colonization in dermatologic patients in Germany. J Dtsch Dermatol Ges 2015; 13 (Suppl. 10) 1015-1022.
    CrossrefPubMedGoogle Scholar
  • 31 Schwendler M, Huebner C, Flessa S. Costs and revenues of MRSA eradication in outpatients with chronic wounds – reimbursement of MRSA eradicatio. J Dtsch Dermatol Ges 2015; 13 (Suppl. 01) 58-61.
    PubMedGoogle Scholar
  • 32 Jockenhöfer F. et al. Bacterial spectrum colonizing chronic leg ulcers. J Dtsch Dermatol Ges 2014; 12 (Suppl. 12) 1121-1127.
    PubMedGoogle Scholar